UPDATE: Read the latest update regarding our response to the novel coronavirus (COVID-19) situation. READ MORE.  

Consultation commences on next stage of Laneway Treatment Trial in Palmerston

City of Palmerston is continuing its consultation commitment and encouraging feedback to guide decision-making on laneway treatments, including closures in Palmerston.  

Council has been trialling treatments in 11 laneways across three Palmerston suburbs, to assess if the measures taken will help discourage anti-social behaviour in these areas. 

Subject to community feedback, Council is proposing to modify the treatments by adding either temporary full-time or night-time closures to seven of the laneways included in the trial, with existing treatments to remain in place for all 11 laneways.  
    
Proposed temporary night-time closures
•    Gumnut Way to Livistona Park, Moulden 
•    Livistona Park to Melastoma Drive, Moulden 
•    Staghorn Court to Livistona Park, Moulden 
•    Staghorn Court to Gumnut Way, Moulden 
•    Priest Circuit to Emery Avenue, Gray 

Proposed temporary full-time closures 
•    Politis Court to Strawbridge Park, Moulden 
•    Politis Court to Strawbridge Crescent, Moulden 

Consultation on the proposed night-time and full-time closures is open to Monday 4 November 2019, with several ways to provide feedback during the 3-week period. Council would also like to hear from residents about laneways in Palmerston that are not included in this trial.

A survey is available online at www.palmerston.nt.gov.au, community meetings will be held in local areas around the laneways under consultation and discussion kiosks in local shopping centres (details on Council’s website).

Once feedback is gathered by Council, and depending on residents’ views, the additional trial treatments are expected to be put in place from the end of November 2019 to March 2020. 

After this time the measures will be reviewed by Council and next steps will be considered, with a final report taking into consideration all consultations and the 11 trial treatments to be presented in March 2020.